Amylyx's neuron-protecting drug slows ALS decline in the late-phase study
A novel combination of compounds has displayed that it can help decrease amyotrophic lateral sclerosis (ALS) by supporting the brain's neurons' inner workings.
After six months of treatment, AMX0035 of Amylyx Pharmaceuticals demonstrated a significant benefit compared to placebo, delaying the fast-acting neurodegenerative disease that robs the patient of their ability to talk, swallow, and eventually move and breathe.
Using a standard clinical metric for gauging patients' abilities to walk, dress, and feed themselves, the company's phase 2/3 study showed that participants taking AMX0035...
